Eradikate Mattifying Acne

Description

UC_EradiKate Mattifying Gel is presented in a dosage form of a gel, with a net weight of 1.7 ounces. The formulation is designed to provide a mattifying effect, suitable for various skin types. The product's specific chemical composition and inactive ingredients are not detailed in the provided information.

Uses and Indications

This drug is indicated for the treatment of acne. It helps keep the skin clear of new acne blemishes.

Dosage and Administration

Healthcare professionals are advised to instruct patients to apply a thin, even layer of the product to clean, dry skin in the morning and/or evening. Care should be taken to avoid the eye area. The application should occur after any treatment steps and prior to the application of makeup and sunscreen.

Initial dosing should begin with one application daily to minimize the risk of excessive skin drying. Patients may gradually increase the frequency to two or three times daily as tolerated or as directed by a healthcare provider. In cases where bothersome dryness or peeling occurs, it is recommended to reduce the application frequency to once daily or every other day.

Contraindications

Use is contraindicated in individuals who are unable to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought or contact with a poison control center is advised.

Warnings and Precautions

FOR EXTERNAL USE ONLY. This product is intended solely for topical application. It is imperative that healthcare professionals advise patients to avoid ingestion, as swallowing the product necessitates immediate medical attention or contact with a poison control center.

Skin irritation or dryness may occur, particularly if the patient concurrently uses another topical acne medication. To mitigate the risk of adverse effects, it is recommended that only one topical acne treatment be utilized at a time. Should irritation arise, patients should discontinue use of all topical acne medications and consult a healthcare provider for further guidance.

No specific general precautions or laboratory tests have been identified for this product. However, vigilance in monitoring for skin reactions is advised to ensure patient safety and treatment efficacy.

Side Effects

Patients should be aware that this product is for external use only. When using this product, skin irritation or dryness may occur, particularly if another topical acne medication is used concurrently. In such cases, it is advised to limit the use to one topical acne medication at a time to minimize the risk of irritation.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation or dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications should be considered to alleviate symptoms. Monitoring for signs of skin irritation is recommended when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Eradikate Mattifying Acne (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be closely monitored when using this medication, as excessive drying of the skin may occur. It is recommended to initiate treatment with one application daily, gradually increasing to two or three times daily as needed or directed by a healthcare professional. In cases where bothersome dryness or peeling develops, the frequency of application should be reduced to once a day or every other day.

Healthcare providers should ensure that this medication is kept out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or a poison control center should be contacted.

Geriatric Use

There is no specific information regarding the use of Eradikate Mattifying Acne Gel Cream in geriatric patients. The prescribing information does not provide details on dosage adjustments, safety concerns, or special precautions that may be necessary for elderly patients. Therefore, healthcare providers should exercise caution and consider individual patient factors when prescribing this medication to geriatric patients, as the absence of specific data necessitates careful monitoring and assessment of treatment efficacy and safety in this population.

Pregnancy

Safety during pregnancy has not been established for this medication. It is not recommended for use during pregnancy due to potential risks to the fetus. There may be risks associated with the use of salicylic acid during pregnancy; therefore, healthcare providers should be consulted for advice regarding its use.

Healthcare professionals are advised to discuss the potential risks and benefits with pregnant patients or women of childbearing potential. Additionally, dosage modifications may be necessary, and appropriate use should be determined in consultation with a healthcare provider.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to dosage adjustments, special monitoring, or precautions. Therefore, there is no available information regarding the use of this medication in individuals with compromised liver function. It is recommended that healthcare providers exercise caution and consider the overall clinical context when prescribing this medication to patients with hepatic impairment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or toxicology experts for guidance on specific management protocols and interventions tailored to the situation.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. Instruct patients that if the medication is swallowed, they should seek medical help immediately or contact a poison control center for assistance. It is important for patients to understand the urgency of this action to ensure their safety and the safety of others.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a cool, dry place to maintain its integrity and efficacy. Proper storage conditions are crucial to ensure the product remains effective throughout its shelf life.

Additional Clinical Information

Patients should apply the medication in the morning and/or evening, using a thin, even layer on clean, dry skin while avoiding the eye area. It is recommended to apply the product after treatment steps and before makeup and SPF. To minimize the risk of excessive skin dryness, patients should begin with one application daily, gradually increasing to two or three times daily as needed or directed by a clinician. If bothersome dryness or peeling occurs, patients should reduce the frequency of application to once a day or every other day.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Eradikate Mattifying Acne, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)